Sort
10,766 grants matching “checkpoint inhibitor”
Drugging EBNA1 to Treat EBV-Associated Cancers
$570,817Troy E Messick · Wistar Institute · R01 · FY2022 · CA
Drugging EBNA1 to Treat EBV-Associated Cancers
$570,817Troy E Messick · Wistar Institute · R01 · FY2023 · CA
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy
$570,782T.-C. Wu · Johns Hopkins University · R01 · FY2023 · CA
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1
$570,647Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U01 · FY2023 · AI
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancer
$570,587Quynh-Thu X Le · Stanford University · R01 · FY2022 · DE
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
$570,541Behnam Badie · Beckman Research Institute/City Of Hope · R01 · FY2024 · NS
Elucidating Mechanism of Immune Evasion in Head and Neck Cancers
$570,401Jing Hong Wang · University Of Colorado Denver · R01 · FY2020 · DE
Nanoconjugate delivery of proliferation and checkpoint inhibitors to treat glial tumors
$570,320Julia Y Ljubimova · Cedars-Sinai Medical Center · R01 · FY2020 · CA
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research
$570,252Steffi Oesterreich · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Mechanism of LSD1 Function and Its Therapeutic Application for Progressive Oral Malignancy
$570,216Manish Bais · Boston University Medical Campus · R01 · FY2022 · DE
Project 3: Inhibiting FAK to enhance immune checkpoint inhibitor therapy in LKB1-mutant lung adenocarcinoma
$569,902Adam I Marcus · Emory University · P01 · FY2023 · CA
Molecular Basis for Myelodysplasia Induced by U2AF1 Mutations
$569,754Golam Mohi · University Of Virginia · R01 · FY2024 · HL
Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma
$569,704Chun Li · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
$569,160Zihai Li · Ohio State University · R01 · FY2021 · CA
The NOTCH Signaling Pathway in Large Vessel Vasculitis
$569,098Cornelia M Weyand · Mayo Clinic Rochester · R01 · FY2021 · HL
Release of interleukin-1a as a mediator of immune evasion in cancer
$568,538Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
$568,496Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2022 · CA
Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
$568,496Chad V Pecot · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Innate lymphoid cell regulation of the host-microbiota interactions in cancer
$568,491Gregory F Sonnenberg · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.
$568,456Nicole Franziska Steinmetz · University Of California, San Diego · U01 · FY2019 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$568,426Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA
Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens
$568,413William C Hahn · Dana-Farber Cancer Inst · U01 · FY2021 · CA
Finding the optimal balance of immunotherapy efficacy and toxicity.
$568,167David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2023 · AI
Credentialing Models of Invasive Lobular Breast Cancer for Translational Research
$568,084Steffi Oesterreich · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
(8) Mechanisms of autoimmune endocrine diseases in patients receiving checkpoint inhibitors
$568,064Kevan C Herold · Yale University · R01 · FY2019 · CA